CSIR-National Chemcial Laboratory (NCL) has developed an anti-tuberculosis cocrystal drug, pitched to be a promising one through its stable formulation of 4-FDC (4 drugs fixed dosage). Tuberculosis is still rampant among Indians and is one of the main killer diseases globally. As per the recommendation by the World Health Organisation (WHO), Rifampicin (RIF), Isoniazid (INH), Pyrazinamide (PZA), and Ethambutol dihydrochloride (EDH) drugs are used for the treatment of TB.
The use of a fixed-dose combination (2-drug, 3-drug and 4-drug FDCs) for the treatment of tuberculosis was first recommended in 1994 by the WHO and International Union against Tuberculosis and Lung Disease (IUATLD). In 1999, the 4-drug FDC tablet was included in the WHO Model List of Essential Drugs inclusive of these four drugs. The 4-FDC tablets, however, had quality and stability issues, including poor…
